You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
This project evaluates radiopharmaceutical dose administration in nuclear medicine procedures by comparing typical administered doses with national Diagnostic Reference Levels (DRL). The study aims to assess dose optimization practices and ensure radiation safety compliance.
Biostatistician and Researcher focusing on: Early Phase Oncology Dose Optimization, Rare Diseases, Time to Event Data, Longitudinal Data, Bayesian Variable Selection, Multivariate Joint Modeling
🧬 Model and optimize CAR-T therapy for glioblastoma using advanced spatial fractional reaction-diffusion techniques and tumor microenvironment insights.
LOGOS (Longitudinal Optimization of Global Outcomes and Strategies) — Bridging mathematical treatment theory and clinical evidence through PK/PD modeling and patient-level prediction.
LOGOS (Longitudinal Optimization of Global Outcomes and Strategies) — Mathematical optimization of finite-course PK/PD regimens using clinical pharmacological data and constrained optimal control.
LOGOS (Longitudinal Optimization of Global Outcomes and Strategies) — Constrained mathematical optimization of finite-course PK/PD regimens using individual pharmacological models.
LOGOS (Longitudinal Optimization of Global Outcomes and Strategies): A mathematical framework for PK/PD treatment cycling, recovery dynamics, and clinical restart decisions.